Treatment Advances

July 22, 2024

Is age just a number? Dr. Julio Chavez shares multicenter findings on how CAR T therapy can be effective in those 80 and older.

July 17, 2024

Discover insights from Dr. Ryan Jacobs on AZD0486, a new bispecific antibody for relapsed or refractory lymphoma patients.

June 18, 2024

Dr. David Miklos joins HealthTree Foundation to discuss CAR T-cell advances and what they mean for DLBCL patients.

May 31, 2024

Learn about Loncastuximab Tesirine (Zynlonta), an FDA-approved conjugated antibody for patients with relapsed or refractory DLBCL.

May 09, 2024

Researchers studied whether certain factors influence the need for blood transfusions in DLBCL patients receiving CAR T-cell therapy.

May 02, 2024

Explore Bispecific Antibodies, a promising new treatment option for relapsed/refractory DLBCL. Learn how they work, side effects, and approved therapies.

April 15, 2024

Immunotherapy offers a promising avenue for patients who have exhausted conventional therapies. Dr. Yilmaz shares updates about this treatment with HealthTree.

April 10, 2024

The FDA requests more data on odronextamab for follicular lymphoma & DLBCL, delaying approval decision. Learn more about odronextamab and the ongoing trials.

April 01, 2024

UT Southwestern has a unique initiative known as the CNS Lymphoma Task Force. This initiative aims to develop better treatment options for these patients.

March 04, 2024

Combination of tafasitamab and lenalidomide is an effective treatment option for patients who are transplant ineligible and have relapsed or refractory DLBCL.